Yukang Lin

2.9k citations

58 papers · 2.3k indexed · 1 hit paper · h-index 28

Oncology top 2%
Radiology, Nuclear Medicine and Imaging top 2%
Molecular Biology
Immunology top 5%
Genetics top 5%

Co-authors: Oliver W. Press Brian G. Till Michael C. Jensen Jinjuan Wang John M. Pagel Philip D. Greenberg Ajay K. Gopal Andrew Raubitschek
Topics: Radiopharmaceutical Chemistry and Applications (28 papers)Monoclonal and Polyclonal Antibodies Research (24 papers)Lymphoma Diagnosis and Treatment (17 papers)
Cited by: Oncology Radiology, Nuclear Medicine and Imaging Immunology
Journals: Journal of the American Chemical Society Blood The Journal of Immunology
Partner nations: United States South Africa Canada

In The Last Decade

Yukang Lin

57 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

2012 431 citations Brian G. Till, Michael C. Jensen et al. Blood profile →

Peers

Countries citing papers authored by Yukang Lin

Since Specialization

Citations

This map shows the geographic impact of Yukang Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yukang Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yukang Lin more than expected).

Fields of papers citing papers by Yukang Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yukang Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yukang Lin. The network helps show where Yukang Lin may publish in the future.

Co-authorship network of co-authors of Yukang Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Yukang Lin. A scholar is included among the top collaborators of Yukang Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yukang Lin. Yukang Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A perspective on the application of macrocyclic design strategies in antitumor drugs 2025 ·Bioorganic Chemistry ·(unknown),Yukang Lin,Junjie Cai,Zhimin Zou,Pei‐Liang Zhao	2
2	Structure-Guided Discovery of Novel N⁴-(Substituted Thiazol-2-yl)-N²-(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability 2025 ·Journal of Medicinal Chemistry ·Bei Zhang,(unknown),Yukang Lin,Ting Wang,Lin Chen,Jing Cai,(unknown),Peng-Cheng Diao,(unknown),Yanting Zhang,Wen‐Wei You,Jingkao Chen,Pei‐Liang Zhao	4
3	Targeting hyperactive mitochondria in activated HSCs and inhibition of liver fibrogenesis in mice using sorafenib complex micelles 2024 ·International Journal of Pharmaceutics ·(unknown),Yuting Qin,Lei Li,(unknown),Wenhui Zhang,(unknown),(unknown),(unknown),(unknown),Tianle Zhou,Yukang Lin,Yuping Chen	1
4	A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer 2022 ·Translational Lung Cancer Research ·Zhenyang Zhang,(unknown),Weijing Cai,Zhi-Nuan Hong,(unknown),Yukang Lin,(unknown),Zhiwei Lin,Daniel C. Christoph,Hanibal Bohnenberger,Lucyna Kępka,Wolfgang M. Brueckl,Paul Van Houtte,Mingqiang Kang,(unknown)	7
5	Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA 2020 ·Molecular Cancer Therapeutics ·Johnnie J. Orozco,Aimee L. Kenoyer,Yukang Lin,Shyril O’Steen,(unknown),(unknown),(unknown),Mark D. Hylarides,Darrell R. Fisher,(unknown),Donald K. Hamlin,D. Scott Wilbur,Kelly Davis Orcutt,K. Dane Wittrup,Damian J. Green,Ajay K. Gopal,Brian G. Till,Brenda M. Sandmaier,Oliver W. Press,John M. Pagel	8
6	Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas 2017 ·Cancer Research ·Shyril O’Steen,Damian J. Green,Ajay K. Gopal,Johnnie J. Orozco,Aimee L. Kenoyer,Yukang Lin,D. Scott Wilbur,Donald K. Hamlin,Darrell R. Fisher,Mark D. Hylarides,Theodore A. Gooley,(unknown),Brian G. Till,Oliver W. Press	23
7	Pretargeting with bispecific fusion proteins facilitates delivery of nanoparticles to tumor cells with distinct surface antigens 2017 ·Journal of Controlled Release ·Qi Yang,Christina L. Parker,Yukang Lin,Oliver W. Press,Steven I. Park,Samuel K. Lai	17
8	Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers 2016 ·Cancer Research ·Damian J. Green,Shani L. Frayo,Yukang Lin,Donald K. Hamlin,Darrell R. Fisher,Sofia H.L. Frost,Aimee L. Kenoyer,Mark D. Hylarides,Ajay K. Gopal,Theodore A. Gooley,Johnnie J. Orozco,Brian G. Till,Shyril O’Steen,Kelly Davis Orcutt,D. Scott Wilbur,K. Dane Wittrup,Oliver W. Press	22
9	Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models 2015 ·PLoS ONE ·Sofia H.L. Frost,Shani L. Frayo,Brian W. Miller,Johnnie J. Orozco,Garrett C. Booth,Mark D. Hylarides,Yukang Lin,Damian J. Green,Ajay K. Gopal,John M. Pagel,Tom Bäck,Darrell R. Fisher,Oliver W. Press	27
10	A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies 2013 ·Cancer Research ·Damian J. Green,Nural Orgun,Jon C. Jones,Mark D. Hylarides,John M. Pagel,Donald K. Hamlin,D. Scott Wilbur,Yukang Lin,Darrell R. Fisher,Aimee L. Kenoyer,Shani L. Frayo,Ajay K. Gopal,Johnnie J. Orozco,Theodore A. Gooley,Brent L. Wood,William Bensinger,Oliver W. Press	40
11	Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma 2013 ·PLoS ONE ·Lihua E. Budde,Carolina Berger,Yukang Lin,Jinjuan Wang,(unknown),(unknown),(unknown),David M. Spencer,Brian G. Till,Michael C. Jensen,Stanley R. Riddell,Oliver W. Press	160
12	CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial resultsbreakdown → 2012 ·Blood ·Brian G. Till,Michael C. Jensen,Jinjuan Wang,Xiaojun Qian,Ajay K. Gopal,David G. Maloney,Catherine Lindgren,Yukang Lin,John M. Pagel,Lihua E. Budde,Andrew Raubitschek,Stephen J. Forman,Philip D. Greenberg,Stanley R. Riddell,Oliver W. Press	431
13	Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma 2011 ·Clinical Cancer Research ·Steven Park,(unknown),(unknown),Donald K. Hamlin,Yukang Lin,D. Scott Wilbur,Patrick S. Stayton,Nural Orgun,Mark D. Hylarides,Franz Buchegger,Aimee L. Kenoyer,(unknown),Ajay K. Gopal,Damian J. Green,John M. Pagel,Oliver W. Press	27
14	Extracorporeal Adsorption Therapy: A Method to Improve Targeted Radiation Delivered by Radiometal-Labeled Monoclonal Antibodies 2008 ·Cancer Biotherapy and Radiopharmaceuticals ·Eneida R. Nemecek,Damian J. Green,Darrell R. Fisher,John M. Pagel,Yukang Lin,Ajay K. Gopal,Lawrence D. Durack,Joseph G. Rajendran,D. Scott Wilbur,Rune Nilsson,Bengt Sandberg,Oliver W. Press	5
15	Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane 2008 ·The Journal of Immunology ·Scott E. James,Philip D. Greenberg,Michael C. Jensen,Yukang Lin,Jinjuan Wang,Brian G. Till,Andrew Raubitschek,Stephen J. Forman,Oliver W. Press	196
16	A Genetically Engineered Anti-CD45 Single-Chain Antibody-Streptavidin Fusion Protein for Pretargeted Radioimmunotherapy of Hematologic Malignancies 2006 ·Cancer Research ·Yukang Lin,John M. Pagel,Donald B. Axworthy,Anastasia Pantelias,(unknown),Oliver W. Press	51
17	Race, education, and knowledge of bone marrow registry: Indicators of willingness to donate bone marrow among African Americans and Caucasians 2004 ·Transplantation Proceedings ·Adedayo A. Onitilo,Yukang Lin,Eni C. Okonofua,(unknown),(unknown),(unknown)	19
18	An oncolytic measles virus engineered to enter cells through the CD20 antigen 2003 ·Molecular Therapy ·Amanda D. Bucheit,Shaji Kumar,Deanna M. Grote,Yukang Lin,Veronika von Messling,Roberto Cattaneo,Adele K. Fielding	72
19	Preclinical Evaluation of a Humanized NR-LU-10 Antibody-Streptavidin Fusion Protein for Pretargeted Cancer Therapy 2001 ·Cancer Biotherapy and Radiopharmaceuticals ·(unknown),James Sanderson,Donald B. Axworthy,Yukang Lin,Mark D. Hylarides,Jody Schultz	28
20	Molecular cloning of the meiosis-induced rec10 gene of Schizosaccharomyces pombe 1995 ·Current Genetics ·Yukang Lin,Gerald R. Smith	25

About Yukang Lin

Yukang Lin is a scholar working on Radiology, Nuclear Medicine and Imaging, Pathology and Forensic Medicine and Oncology, having authored 58 papers that have together received 2.3k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (28 papers), Monoclonal and Polyclonal Antibodies Research (24 papers) and Lymphoma Diagnosis and Treatment (17 papers). The work is most often cited by research in Oncology (1.3k citations), Radiology, Nuclear Medicine and Imaging (774 citations) and Immunology (494 citations). Yukang Lin has collaborated with scholars based in United States, South Africa and Canada. Frequent co-authors include Oliver W. Press, Brian G. Till, Michael C. Jensen, Jinjuan Wang, John M. Pagel, Philip D. Greenberg, Ajay K. Gopal, Andrew Raubitschek, Stephen J. Forman and Stanley R. Riddell. Their work appears in journals such as Journal of the American Chemical Society, Blood and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact